Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: A case series from two national pharmacovigilance centres

European Journal of Clinical Pharmacology

Volumn 68, Issue 7, 2012, Pages 1065-1072

  Harrison Woolrych, Mira ^a   Härmark, Linda ^b,d   Tan, Ming ^a   Maggo, Simran ^c   Van Grootheest, Kees ^b,d  

^a New Zealand Pharmacovigilance Centre   (New Zealand)

^b NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adverse events; Bleeding; Epistaxis; Haemorrhage; Varenicline

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ATORVASTATIN; CALCIUM CARBONATE; CILAZAPRIL; CITALOPRAM; ESTRADIOL; FUROSEMIDE; GLIBENCLAMIDE; GLYCERYL TRINITRATE; IBUPROFEN; MEDROXYPROGESTERONE; METFORMIN; METOPROLOL; NIFEDIPINE; NORTRIPTYLINE; OMEPRAZOLE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SIMVASTATIN; THIAZIDE DIURETIC AGENT; THYROXINE; TIOTROPIUM BROMIDE; VARENICLINE; WARFARIN;

ADULT; AGED; ANGER; ARTICLE; BLEEDING; BLOOD PRESSURE; CASE REPORT; CASE STUDY; COHORT ANALYSIS; CONJUNCTIVAL HEMORRHAGE; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SURVEILLANCE PROGRAM; DYSPHONIA; EPISTAXIS; FEMALE; FLATULENCE; FOLLOW UP; GINGIVA BLEEDING; HEMATOCHEZIA; HEMATOMA; HEMOPTYSIS; HUMAN; HYPERMENORRHEA; MALE; MOOD CHANGE; MUSCLE SPASM; NAUSEA; NETHERLANDS; NEW ZEALAND; NIGHT SWEAT; ORAL BLEEDING; ORAL BLISTER; PRIORITY JOURNAL; SIDE EFFECT; SMOKING CESSATION; SORE THROAT; STOMACH DISEASE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; VOMITING;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; BENZAZEPINES; DATABASES, FACTUAL; EPISTAXIS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; NEW ZEALAND; NICOTINIC AGONISTS; PHARMACOVIGILANCE; QUINOXALINES; SMOKING CESSATION; YOUNG ADULT;

EID: 84864288697     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1220-y     Document Type: Article

References (31)

1. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L et al (2008) Pharmacotherapies for smoking cessation: a metaanalysis of randomized controlled trials. Can Med Assoc J 179 (2):135-144 (Pubitemid 352020119)
2. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296(1):47-55
3. Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CBJr, Gong J, Williams KE, Reeves KR (2008) Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax 63(8):717-24
4. Agency EM (2011) Champix: procedural steps taken and scientific information after the authorisation. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific- information-after-authorisation/human/000699/WC500025256.pdf. Accessed June 2011
5. Federal Drug Administration (2009) Varenicline and bupropion: reports of suicidality associated with the use of varenicline and bupropion. FDA Drug Saf Newsl 2(1)
6. Harrison-Woolrych M (2011) Psychiatric reactions with varenicline: interim results from intensive monitoring in New Zealand. Prescriber update 2009. Available at: http://medsafe.govt.nz/profs/PUarticles/varencline. Accessed 30 February 2011
7. Pfizer (2011) New Zealand data sheet for Champix. Available at: http://www.medsafe.govt.nz/profs/datasheets. Accessed June 2011
8. Pfizer (2011) Summary of Product Characteristics for Champix. Available at: http://www.medicines.org.uk/emc/document.documentid019045. Accessed June 2011
9. Pharmac (2010) Decision on proposals for venlafaxine, etanercept, varenicline, sunitinib and adalimumab. Available at: http://www.pharmac.govt.nz/ 2010/09/28/2010-09-28%20Pfizer%20Notification.pdf. Accessed June 2011
10. Harrison-Woolrych M, Coulter DM (2006) PEM in New Zealand. In: Mann R, Andrews EB (eds) Pharmacovigilance, 2nd edn. John Wiley and Sons, Chichester, pp 313-328
11. Kunac DL, Harrison-Woolrych M, Tatley MV (2008) Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 121(1283):76-89
12. Karch FE, Lasagna L (1975) Adverse drug reactions. A critical review. JAMA 234(12):1236-1241
13. Van Grootheest KVPE (2007) Pharmacovigilance in the Netherlands. In: Mann R, Andrews EB (eds) Pharmacovigilance, Secondth edn. John Wiley and Sons, Chichester, pp 277-285
14. Harmark L, van Puijenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf 34(3):221-231.
15. Cox RA, Varenicline C (2009) Evaluation of the utility of spontaneous consumer reports of suspected adverse effects on internet sites. Drug Saf 32(10):903-904
16. Kamath S, Lip GYH (2003) Fibrinogen: biochemistry, epidemiology and determinants. Q J Med 96(10):711-729 (Pubitemid 37259361)
17. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H (1990) Plasma fibrinogen and coronary risk factors: The Scottish Heart Health Study. J Clin Epidemiol 43(9):913-919 (Pubitemid 20345969)
18. Miller G (1992) Hemostasis and cardiovascular risk. The British and European experience. Arch Pathol Lab Med 116(12):1318-1321
19. Meade TW IJ, Stirling Y (1987) Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 31(2):986-988 (Pubitemid 17150856)
20. de Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C (1996) Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 121 (2):185-191 (Pubitemid 26125975)
21. Tuut M, Hense H-W (2001) Smoking, other risk factors and fibrinogen levels: evidence of effect modification. Ann Epidemiol 11(4):232-238 (Pubitemid 32288853)
22. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH (2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 26 (17):1765-1773 (Pubitemid 41219850)
23. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM (2007) Systemic effects of smoking. Chest 131(5): 1557-1566 (Pubitemid 46762366)
24. Dietrich T, Bernimoulin J-P, Glynn RJ (2004) The effect of cigarette smoking on gingival bleeding. J Periodontol 75(1): 16-22 (Pubitemid 38312765)
25. Nair P, Sutherland G, Palmer RM, Wilson RF, Scott DA (2003) Gingival bleeding on probing increases after quitting smoking. J Clin Periodontol 30(5):435-437 (Pubitemid 38037102)
26. Flanagan RJ, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 23(S1):S27-S41
27. Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HGM, Egberts TCG (2011) Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 89(1):89-96
28. Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. Physicians Postgraduate Press, Memphis 29.
29. McNeil J, Piccenna L, Ioannides-Demos L (2010) Smoking cessation - recent advances. Cardiovasc Drugs Ther 24(4): 359-367
30. Rollema H, Wilson GG, Lee TC, Folgering JHA, Flik G (2011) Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Neurochem Int 58(1):78-84
31. Schedel A, Thornton S, Schloss P, Kluter H, Bugert P (2011) Human platelets express functional {alpha}7-nicotinic acetylcholine receptors. Arterioscler Thromb Vasc Biol 31(4):928-934